CELMoDs for the treatment of newly diagnosed and HR smoldering MM

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase modulators (CELMoDs) in newly diagnosed multiple myeloma (NDMM) and high-risk smoldering multiple myeloma.During this interview, Richardson discusses the use of CELMoDs, particularly iberdomide, in earlier lines of therapy. Richardson reviews clinical data on activity and tolerability in newly diagnosed patients, including those who are transplant ineligible, as well as in combination with standard therapies. Richardson also explores the potential role of CELMoDs in maintenance strategies, risk-adapted approaches, and in high-risk smoldering multiple myeloma. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.